Fludarabine/busulfan conditioning based allogeneic hematopoietic cell transplantation for myelofibrosis: Role of ruxolitinib in improving survival outcomes
Primary myelofibrosis (MF) is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid proliferation, splenomegaly, bone marrow fibrosis, and heterogenous symptom burden [1-3]. Non-transplant treatment options have traditionally included cytoreductive therapies (hydroxyurea, busulfan, interferon- α), immunomodulatory drugs, androgens, splenic irradiation and splenectomy – though these are primarily palliative [4]. In the last decade, major advances in the understanding of the molecular basis of MF have been achieved, importantly the pivotal role of the JAK-STAT pathway.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Saurabh Chhabra, Ravi K. Narra, Ruizhe Wu, Aniko Szabo, Gemlyn George, Laura C. Michaelis, Anita D'Souza, Binod Dhakal, William R. Drobyski, Timothy S. Fenske, James H. Jerkins, Marcelo C. Pasquini, R. Douglas Rizzo, Wael Saber, Nirav N. Shah, Bronwen E. Source Type: research
More News: Biology | Hematology | Molecular Biology | Myeloproliferative Disorders | Palliative | Splenectomy | Transplants